Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer

CONCLUSION: Our data indicate, for the first time, that CDK7-targeted therapy in ER+ breast cancer ameliorates tamoxifen resistance, at least in part, by inhibiting cancer stemness. Thus, targeting CDK7 might represent a potential approach for relieving tamoxifen resistance in ER+ breast cancer.PMID:35000145 | DOI:10.1007/s43440-021-00346-9

Source: Pharmacological Reports - January 9, 2022 Category: Drugs & Pharmacology Authors: Yasmin M Attia Salama A Salama Samia A Shouman Cristina Ivan Abdelrahman M Elsayed Paola Amero Cristian Rodriguez-Aguayo Gabriel Lopez-Berestein Source Type: research